Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
GSK NDA for Myelofibrosis Candidate Gets FDA Acceptance
09:47am, Thursday, 18'th Aug 2022
GSK's NDA for momelotinib for treating myelofibrosis was based on data from key phase III studies, including the pivotal MOMENTUM study.
Does Editas (EDIT) Have the Potential to Rally 65% as Wall Street Analysts Expect?
01:55pm, Tuesday, 16'th Aug 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the positiv
A Comprehensive Guide to Genomic ETFs
12:03pm, Friday, 12'th Aug 2022
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Editas' (EDIT) Loss Narrows in Q2, Revenues Trump Estimates
04:30pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Editas (EDIT) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates. Focus remains on the lead candidate, EDIT-101.
Editas Medicine, Inc. (EDIT) CEO Gilmore O'Neill on Q2 2022 Results - Earnings Call Transcript
10:19am, Thursday, 04'th Aug 2022
Editas Medicine, Inc. (NASDAQ:EDIT ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Ron Moldaver - Investor Relations Jim Mullen - Executive Chairman Gilmore O'Neill -
Why Editas Medicine Was Winning on Wednesday
08:41pm, Wednesday, 03'rd Aug 2022 The Motley Fool
The company's top line really caught investors' eye.
Why Editas Medicine Was Winning on Wednesday
04:41pm, Wednesday, 03'rd Aug 2022
The company's top line really caught investors' eye.
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
11:55am, Wednesday, 03'rd Aug 2022 Zacks Investment Research
Editas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine Announces Second Quarter 2022 Results and Business Updates
10:29am, Wednesday, 03'rd Aug 2022 GlobeNewswire Inc.
Appointed Baisong Mei, M.D., Ph.D., Chief Medical Officer, strengthening senior leadership team
Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates
09:02am, Wednesday, 03'rd Aug 2022
Editas (EDIT) delivered earnings and revenue surprises of 7.14% and 19.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease
10:30am, Wednesday, 27'th Jul 2022 GlobeNewswire Inc.
Successful engraftment of first patient dosed with EDIT-301 for sickle cell disease
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
10:26am, Tuesday, 26'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wedne
Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates
06:26am, Tuesday, 26'th Jul 2022
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesd
Down 35% This Year, Is This Small-Cap Stock a Buy?
02:30pm, Thursday, 21'st Jul 2022 The Motley Fool
This biotech could be a steal at its current levels, but it could also be a trap.
Editas Medicine Reports Inducement Grant to New Chief Medical Officer
08:30pm, Wednesday, 20'th Jul 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of an inducement award to the Company’s newly
